ArticleCell communication and signaling : CCS2025
LIMCH1 inhibits antitumor immunity by upregulating PDL1 in triple-negative breast cancer.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges.International journal of cancer · 2026Review
- Epigenome-Wide DNA Methylation Levels During Pregnancy: Associations with Parity Across Diverse Populations.Epigenomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundBreast cancer is one of the most common malignancies globally. Despite advancements in treatment, efficacy for certain subtypes such as triple-negative breast cancer (TNBC) remains limited. Immunotherapy has provided new hope for advanced breast cancer, particularly triple-negative breast cancer (TNBC), though its effectiveness varies by tumor type and patient differences. LIMCH1, a relatively understudied LIM-domain protein, has been linked to cytoskeletal regulation and various cancers, including lung, cervical, and renal carcinoma. This study aims to investigate LIMCH1 expression and its impact in breast cancer.
methodsThe prognostic role of LIMCH1 in multiple cancers was analyzed using the TCGA database, and its expression in breast cancer was validated through immunohistochemistry (IHC) on breast cancer tissue microarrays. LIMCH1 overexpression and knockdown TNBC cell lines were constructed, and CCK-8, colony formation, transwell migration, and wound healing assays were performed to assess the effect of LIMCH1 on cell proliferation and migration. PD-L1 expression and selected immune-related proteins, such as CD3, CD4, CD8, and p-ERK1/2, were evaluated by flow cytometry, immunofluorescence, or Western blotting. A mouse allograft model was established to evaluate LIMCH1’s role in tumor growth and T-cell infiltration within the TIME.
resultsLIMCH1 was highly expressed in breast cancer and associated with poor prognosis. Bioinformatics analysis revealed that high LIMCH1 expression correlates with an immunosuppressive state. Functional assays showed that LIMCH1 overexpression promoted proliferation and migration, while knockdown inhibited these phenotypes. Mechanistic studies indicated that LIMCH1 upregulated PD-L1 via MAPK pathway activation, suppressed CD4 + and CD8 + T-cell infiltration, and led to an immunosuppressive tumor microenvironment. High LIMCH1 expression was also linked to low response rates to anti-PD-1 therapy, suggesting it may influence immunotherapy efficacy.
conclusionLIMCH1 promotes tumor activity in breast cancer by activating the MAPK pathway, upregulating PD-L1, and enhancing immune evasion. LIMCH1 may serve as a potential therapeutic target for breast cancer immunotherapy. This study provides new evidence for the role of LIMCH1 in breast cancer and offers new insights and directions for precision therapy of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.